First placebo-controlled trial of benznidazole evaluating safety and efficacy in Pediatric patients 6 to 12 years old with Chagas disease

Trial Profile

First placebo-controlled trial of benznidazole evaluating safety and efficacy in Pediatric patients 6 to 12 years old with Chagas disease

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Benznidazole (Primary)
  • Indications Chagas disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2017 New trial record
    • 29 Aug 2017 Results published in the FDA Media Release
    • 29 Aug 2017 Based on the data from this and other trial (see profile 288394), the U.S. Food and Drug Administration has granted accelerated approval to benznidazole for use in children ages 2 to 12 years old with Chagas disease, as reported in a FDA media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top